Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Eli LillyFinanical Reports

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Yangtze River Pharmaceutical's Tadalafil Hydrochloride Tablets Approved for ED Treatment in China
Product approvals

Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China

Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors
CancerEPA: IPN

Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors

Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer IngelheimFinanical Reports

Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025

Kelun-Biotech's SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment
Clinical trial approval / initiationHKG: 6990

Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment

Show More